Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (BEAM) is a pioneering biotechnology company developing precision genetic medicines through its innovative base editing platform. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in gene editing technology.
Investors and researchers will find curated press releases covering therapeutic advancements, financial disclosures, and scientific partnerships. Our collection includes updates on BEAM's hematology programs, in vivo editing initiatives, and manufacturing capabilities - all essential for understanding the company's position in genetic medicine.
Key content categories include clinical trial progress for sickle cell disease therapies, intellectual property developments in base editing, and strategic collaborations advancing CRISPR-based treatments. Each update is carefully verified to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to Beam Therapeutics' latest milestones in creating single-edit genetic therapies. Check regularly for authoritative updates on one of biotechnology's most promising precision medicine platforms.
Beam Therapeutics (NASDAQ: BEAM) announced breakthrough initial data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD). The trial demonstrated the first-ever clinical genetic correction of a disease-causing mutation through base editing.
Key findings from the first three single-ascending dose cohorts (15mg, 30mg, and 60mg) showed:
- The third dose level (60mg) achieved mean total AAT of 12.4µM at Day 28, exceeding the protective therapeutic threshold
- Reduction of mutant Z-AAT up to 78%
- Durable, dose-dependent increases in total and functional Alpha-1 Antitrypsin (AAT)
- Favorable safety profile with no serious adverse events or dose-limiting toxicities
The treatment demonstrated potential as a one-time therapy addressing both liver and lung disease in AATD patients. The company plans to continue dose escalation and expects to present updated data from Part A of the trial at a medical conference in H2 2025.
Beam Therapeutics reported its Q4 and full year 2024 financial results and reiterated key milestones for 2025. The company achieved its adult enrollment target in the BEACON trial for BEAM-101 in sickle cell disease, with dosing and updated data expected by mid-2025. Initial data from the Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency is anticipated in the first half of 2025, and dosing in the Phase 1/2 trial of BEAM-301 in glycogen storage disease type 1a is expected to start in early 2025. Beam ended Q4 2024 with $850.7 million in cash and equivalents, projecting a cash runway into 2027.
Financial highlights include:
- Q4 2024 R&D expenses: $101.4 million
- Full year 2024 R&D expenses: $367.6 million
- Q4 2024 G&A expenses: $28.7 million
- Full year 2024 G&A expenses: $111.5 million
- Q4 2024 net loss: $90.4 million, or $1.09 per share
- Full year 2024 net loss: $376.7 million, or $4.58 per share
Beam's strong financial position supports its ongoing and upcoming clinical trials and regulatory activities. The company's focus remains on delivering life-long cures for serious diseases through precision genetic medicines.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, has announced its management's upcoming participation in three major investor conferences in March 2025:
• The TD Cowen 45th Annual Health Care Conference on March 3 at 1:50 p.m. ET
• The Leerink Partners Global Biopharma Conference on March 10 at 1:40 p.m. ET
• The Barclays Global Healthcare Conference on March 11 at 3:30 p.m. ET
The company will participate in fireside chats at each event. Live webcasts will be accessible through Beam's investor website section at www.beamtx.com and will remain archived for 60 days after the presentations.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. John Evans, the company's CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
The event will be accessible to interested parties through a live webcast on the investor section of Beam's website (www.beamtx.com). The presentation recording will remain available on the website for 60 days following the event.
Beam Therapeutics (Nasdaq: BEAM) announced it will present data from the BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease at the 2025 Tandem Meetings in Hawaii. The presentation will feature results previously shown at the ASH Annual Meeting in December 2024, covering seven treated patients. Key findings include robust and durable increases in fetal hemoglobin (HbF), reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and improved markers of hemolysis. The safety profile aligned with expected outcomes for busulfan conditioning and autologous hematopoietic stem cell transplantation. The company plans to present updated trial data in mid-2025.
Beam Therapeutics (NASDAQ: BEAM) announced significant progress in its hematology and genetic disease programs, highlighting key milestones for 2025. The company's BEACON trial for BEAM-101 in sickle cell disease has enrolled over 40 adult patients, with 13 already dosed. Beam expects to dose 30 patients and present updated data by mid-2025.
The company is advancing multiple programs: BEAM-302 for alpha-1 antitrypsin deficiency with initial Phase 1/2 data expected in first half 2025; BEAM-301 for glycogen storage disease type 1a with dosing anticipated in early 2025; and ESCAPE nongenotoxic conditioning program with BEAM-103 antibody study expected by year-end.
Financially, Beam reports estimated $850.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, expecting to fund operations into 2027, including commercial readiness activities for BEAM-101.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines through base editing, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Evans will deliver a presentation on January 13, 2025, at 1:30 p.m. PT in San Francisco. The presentation will be accessible via live webcast on the company's website investor section at www.beamtx.com and will remain available for 60 days after the event.
Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditioning approach to treating sickle cell disease.
The platform consists of two investigational products: BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy designed to elevate fetal hemoglobin (HbF). Key findings showed long-term engraftment of base-edited hematopoietic stem cells, with HbF-containing cells reaching >80% post-transplant and γ-globin levels exceeding 40%. The treatment was well-tolerated, requiring no supportive care.
The company plans to initiate Phase 1-enabling studies by the end of 2024 for both sickle cell disease and beta-thalassemia applications.
Beam Therapeutics announced new data from its BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease (SCD). The trial showed promising results in seven treated patients with follow-up ranging from 1 to 11 months. Key achievements include:
- All patients achieved hemoglobin F levels >60% and hemoglobin S reduction to <40%
- Resolution of anemia and normalized hemolysis markers
- Rapid neutrophil (mean 17.1 days) and platelet (mean 19.1 days) engraftment
- Efficient cell collection with 1-2 mobilization cycles
The safety profile aligned with busulfan conditioning and autologous stem cell transplantation. One patient died from respiratory failure related to busulfan conditioning. No vaso-occlusive crises were reported post-engraftment. Currently, 11 patients have been dosed in the ongoing trial.
Beam Therapeutics (Nasdaq: BEAM) has appointed Sravan K. Emany as Chief Financial Officer, effective December 19, 2024. Emany joins from Ironwood Pharmaceuticals, where he served as CFO and COO. His extensive background includes leadership roles at Integra LifeSciences as Corporate VP of Commercial Excellence and Chief Strategy Officer, and nearly a decade in investment banking at Bank of America, where he led healthcare sector M&A as Managing Director.
CEO John Evans highlighted Emany's exceptional background in capital formation and allocation strategy, noting his importance in guiding Beam through its next growth phase as the company advances multiple clinical programs in hematology and genetic disease. Emany expressed enthusiasm about joining Beam's mission to transform genetic disease treatment through precision medicines.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
